Literature DB >> 15606348

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.

Robert Belshe1, Min-Shi Lee, Robert E Walker, Jeffrey Stoddard, Paul M Mendelman.   

Abstract

Data supporting the use of the live attenuated influenza vaccine (LAIV) in children and adults is reviewed, and the development and characteristics of the vaccine are summarized. The vaccine is highly effective and well tolerated in children and adults from 5 to 49 years of age. Correlates of immune protection include serum hemagglutination-inhibition antibody and secretory immunoglobulin A. Efficacy against antigenically well-matched epidemic influenza strains was high at 92%. In 1 year, despite a significant antigenic change in the epidemic influenza virus that did not match the vaccine, LAIV conferred 86% protection against culture-confirmed illness in children. In the future it is expected that additional studies will support a broadening of the age range for use with the LAIV to prevent influenza in children and adults.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15606348     DOI： 10.1586/14760584.3.6.643

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  50 in total

1.  Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Authors:  Jennifer Humberd Smith; Mark Papania; Darin Knaus; Paula Brooks; Debra L Haas; Raydel Mair; James Barry; S Mark Tompkins; Ralph A Tripp
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

Review 2.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

3.  Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.

Authors:  Diane L Bolton; Kaimei Song; Georgia D Tomaras; Srinivas Rao; Mario Roederer
Journal:  Vaccine       Date:  2016-12-29       Impact factor: 3.641

4.  Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets.

Authors:  Grace L Chen; Ji-Young Min; Elaine W Lamirande; Celia Santos; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Infect Dis       Date:  2011-01-21       Impact factor: 5.226

Review 5.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

6.  Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.

Authors:  Sabine Sereinig; Marina Stukova; Natalia Zabolotnyh; Boris Ferko; Christian Kittel; Julia Romanova; Tatiana Vinogradova; Hermann Katinger; Oleg Kiselev; Andrej Egorov
Journal:  Clin Vaccine Immunol       Date:  2006-08

7.  TIR-Domain-Containing Adapter-Inducing Interferon-β (TRIF) Regulates CXCR5+ T helper Cells in the Intestine.

Authors:  Saravana Kanagavelu; Claudia Flores; Shinichiro Hagiwara; Jose Ruiz; Jinhee Hyun; Ei E Cho; Frank Sun; Laura Romero; David Q Shih; Masayuki Fukata
Journal:  J Clin Cell Immunol       Date:  2016-09-30

8.  Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-11-30

9.  The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus.

Authors:  Amorsolo L Suguitan; Michael P Marino; Purvi D Desai; Li-Mei Chen; Yumiko Matsuoka; Ruben O Donis; Hong Jin; David E Swayne; George Kemble; Kanta Subbarao
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

10.  Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses.

Authors:  James A Wiley; Laura E Richert; Steve D Swain; Ann Harmsen; Dale L Barnard; Troy D Randall; Mark Jutila; Trevor Douglas; Chris Broomell; Mark Young; Allen Harmsen
Journal:  PLoS One       Date:  2009-09-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.